Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > REPL Replimune > Company Profile
REPL Replimune
23.090
+4.200+22.23%
Post Mkt Price
22.800
-0.290-1.26%
Symbol
REPL
Company Name
Replimune
Listing Date
07/20/2018
Establishment Date
2015
CEO
Mr. Philip Astley-Sparke
Market
NASDAQ
Employees
206
Securities Type
DR
Fiscal Year Ends
03-31
Address
500 Unicorn Park Drive,3rd floor
City
Woburn
Province
Massachusetts
Country
United States of America
Zip code
01801
Phone
1-781-222-9600
Profile
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Company Overview
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
CEO: Mr. Philip Astley-Sparke
Market: NASDAQ
Listing Date: 07/20/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist